Amicus Therapeutics

Yahoo Finance • last month

Investment Manager Bets Big on PTCT Stock, Adds 41,000 Shares, According to Recent SEC Filing

Palo Alto Investors LP reported a buy of 41,303 shares of PTC Therapeutics(NASDAQ:PTCT) in its February 17, 2026, SEC filing, with an estimated transaction value of $3.00 million based on quarterly average pricing. What Happened Accordin... Full story

Yahoo Finance • last month

Investment Firm Adds Nearly $4 Milllion Worth of DYN Shares, According to Recent SEC Filing

Key Points 209,523-share increase in Dyne Therapeutics; estimated transaction value $3.97 million (based on quarterly average pricing) Quarter-end position in Dyne Therapeutics rose $12.82 million in value, reflecting both trading and sto... Full story

Yahoo Finance • last month

Catalyst Watch: Jobs report, new Apple products, and a spotlight on software

[New York Stock Exchange] Selcuk Oner/iStock Editorial via Getty Images Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock pric... Full story

Yahoo Finance • 2 months ago

Amicus Therapeutics Non-GAAP EPS of $0.31, revenue of $634M

* Amicus Therapeutics press release [https://seekingalpha.com/pr/20407890-amicus-therapeutics-announces-full-year-2025-financial-results-and-corporate-updates] (FOLD [https://seekingalpha.com/symbol/FOLD]): FY Non-GAAP EPS of $0.31. *... Full story

Yahoo Finance • 2 months ago

Halper Sadeh LLC is Investigating Whether RAPT, CTGO, TBN, FOLD are Obtaining Fair Deals for their Shareholders

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm... Full story

Yahoo Finance • 2 months ago

BioMarin Debt Deal And VOXZOGO Approval Recast Rare Disease Outlook

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. BioMarin Pharmaceutical (NasdaqGS:BMRN) has closed a large debt offering to help fund its pending acquisition of Amicus The... Full story

Yahoo Finance • 2 months ago

Jefferies Downgrades Amicus Therapeutics, Inc. (FOLD) to Buy And Lowers Price Target Amid Takeover Developments

We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. Amicus Therapeutics, Inc. tops our list for being one of the best biotech stocks. TheFly reported on January 22 that Jefferies downgraded FOLD to Buy from Hol... Full story

Yahoo Finance • 3 months ago

All J.P. Morgan's top stock picks for 2026

[Countdown to 2026. Loading year from 2025 to 2026. New year start concept.] SmileStudioAP J.P. Morgan identifies specific traits that define their Best Ideas for 2026. These companies typically possess: * Strong Financial Health: Rob... Full story

Yahoo Finance • 3 months ago

Noteworthy ETF Inflows: XBI, FOLD, MRNA, EXEL

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $218.7 million dollar inflow -- that... Full story

Yahoo Finance • 4 months ago

Catalyst Watch: Defense stocks in play, FOMC minutes, and opening 2026 trades

[Wall Street New York Stock Exchange Stock Market & Government Tariffs] Douglas Rissing Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may i... Full story

Yahoo Finance • 4 months ago

Assessing Amicus Therapeutics (FOLD) Valuation After Its Recent Share Price Rally

Amicus Therapeutics (FOLD) has been quietly rewarding patient holders, with the stock climbing around 44% over the past month and more than 70% in the past 3 months, outpacing many biotech peers. See our latest analysis for Amicus Therape... Full story

Yahoo Finance • 4 months ago

BioMarin snaps up Amicus Therapeutics for $4.8bn amid rare disease push

BioMarin Pharmaceutical has agreed to buy rare disease biotech Amicus Therapeutics, adding three approved or late-stage lysosomal storage disorder therapies to its portfolio. Under the terms of the agreement, BioMarin will pay cash for al... Full story

Yahoo Finance • 4 months ago

Key deals this week: Trump Media & Technology, Howard Hughes, BioMarin Pharmaceutical and more

[Documents about mergers and acquisitions m&a with a pen.] designer491 Here's a list of key deals reported across sectors this week: * BioMarin Pharmaceutical (BMRN [https://seekingalpha.com/symbol/BMRN]) has agreed to acquire [https:/... Full story

Yahoo Finance • 4 months ago

BioMarin (BMRN) Jumps 17.7% on $5-Billion Merger with Amicus

We recently published 10 Firms in the Limelight. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the best performers on Friday. BioMarin Pharmaceutical extended its winning streak to a third straight day on Friday, surging 17.71 perc... Full story

Yahoo Finance • 4 months ago

Amicus (FOLD) Flies to 52-Week High on $5-Billion BioMarin Merger

We recently published 10 Firms in the Limelight. Amicus Therapeutics, Inc. (NASDAQ:FOLD) is one of the best performers on Friday. Amicus Therapeutics soared to a new 52-week high on Friday, jumping 30.21 percent to close at $14.18 apiece... Full story

Yahoo Finance • 4 months ago

Investing.com’s stocks of the week

Investing.com -- It’s been a mixed week for equities, with the rise so far in Friday’s session putting the S&P on track to close flat for the week, while the Nasdaq would post a 0.2% increase. Here are our stocks of the week: Micron Mic... Full story

Yahoo Finance • 4 months ago

BC-Most Active Stocks

NEW YORK (AP) — prices for the Nasdaq composite, NYSE and NYSE American listed most active stocks. Nasdaq most active stocks: Stock Name Volume High Low Last Change ProPhase Labs Inc. 221,499,940 0.1839 0.1376 0.1414 +0.0363 Inspire Vete... Full story

Yahoo Finance • 4 months ago

Amicus Therapeutics (FOLD) Soars to 52-Week High on ‘Strong Buy’ Reco

We recently published 10 Big Names Leaving Wall Street in the Dust; 4 at Fresh Highs. Amicus Therapeutics, Inc. (NASDAQ:FOLD) is one of the best performers on Friday. Amicus jumped to a new 52-week high on Friday, as investors took heart... Full story

Yahoo Finance • 4 months ago

Breakthrough Therapies Advance as Rare Disease Burden Intensifies Across Aging Populations

AUSTIN, Texas, Dec. 04, 2025 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Chronic illnesses and rare disorders among older Americans represent a rapidly intensifying challenge for the U.S. healthcare system, with the National Insti... Full story

Yahoo Finance • 5 months ago

Amicus targets $1B combined sales by 2028 as Galafold and Pompe therapies drive record growth

Earnings Call Insights: Amicus Therapeutics (FOLD) Q3 2025 MANAGEMENT VIEW * Bradley Campbell, CEO, highlighted another quarter of double-digit revenue growth in the Fabry and Pompe core business, stating, “Galafold delivered 13% year-... Full story